Certain debt securities or warrants could be converted into equity, while preferred shares may also be exchangeable for ...

Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage ...

The D.C. biotech also filed a shelf registration statement for $200 million, opening the door for it to raise that money over ...

Brayer covers the Healthcare sector, focusing on stocks such as Vanda, CytomX Therapeutics, and Insmed. According to TipRanks, Brayer has an average return of 6.7% and a 46.15% success rate on ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-2.39 EPS, expectations were ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...

WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug ...